Objective:To investigate the relationship between postprandial blood glucose(PBG),fasting insulin(FINS),and glycated hemoglobin(HbA1c)levels and early diabetic nephropathy in patients with type 2 diabetes.Methods:96 c...Objective:To investigate the relationship between postprandial blood glucose(PBG),fasting insulin(FINS),and glycated hemoglobin(HbA1c)levels and early diabetic nephropathy in patients with type 2 diabetes.Methods:96 cases of type 2 diabetes mellitus treated in our hospital from May 2021 to May 2022 were selected as the research subjects.The patients were divided into two groups according to the urinary albumin excretion rate(UAER),with 53 cases in the type 2 diabetes group(UAER<30μg/min)and 43 cases in the early diabetic nephropathy group(30μg/min≤UAER<300μg/min).PBG,FINS,and HbA1c levels were detected in 87 healthy patients.Results:The levels of PBG,FINS,and HbA1c in the early diabetic nephropathy group were higher than those in the control group(P<0.01)and the type 2 diabetes group(P<0.01).Conclusion:PBG,FINS,and HbA1c are factors affecting the occurrence of diabetic nephropathy in patients with type 2 diabetes;thus,controlling the levels of PBG,FINS,and HbA1c can effectively prevent the occurrence of diabetic nephropathy in type 2 diabetes mellitus.展开更多
目的分析糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)单一及联合检验诊断糖尿病的价值。方法以72例疑似有糖尿病的患者作为临床研究对象,均接受HbA1c、FPG、2 h PG检验,以糖耐量测定为诊断“金标准”。比较HbA1c、FPG、2 ...目的分析糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)单一及联合检验诊断糖尿病的价值。方法以72例疑似有糖尿病的患者作为临床研究对象,均接受HbA1c、FPG、2 h PG检验,以糖耐量测定为诊断“金标准”。比较HbA1c、FPG、2 h PG单一及联合检验的灵敏度、特异度、准确度。结果72例受检者中有58例患者确诊为糖尿病。联合检验的诊断灵敏度、特异度、准确度分别为94.83%、92.86%、94.44%;HbA1c检验的诊断灵敏度、特异度、准确度分别为75.86%、28.57%、66.67%;FPG检验的诊断灵敏度、特异度、准确度分别为81.03%、35.71%、72.22%;2 h PG检验的诊断灵敏度、特异度、准确度分别为77.59%、42.86%、70.83%。联合检验诊断的灵敏度、特异度及准确度均高于其他HbA1c、FPG、2 h PG单一诊断的灵敏度、特异度及准确度,具有统计学意义(P<0.05)。结论HbA1c、FPG、2 h PG联合检验相较单一检验诊断糖尿病具有较高的临床价值,能够为临床治疗提供有价值的参考依据。展开更多
Objective:To explore the anti-diabetic effects and its underlying mechanism of Annona muricata Linn fruit ethanol extract(AME).Methods:Streptozotocin-induced type 2 diabetic(T2DM)mouse model was constructed.Those diab...Objective:To explore the anti-diabetic effects and its underlying mechanism of Annona muricata Linn fruit ethanol extract(AME).Methods:Streptozotocin-induced type 2 diabetic(T2DM)mouse model was constructed.Those diabetic mice were randomly grouped and given 50 mg/kg acarbose or AME(200 mg/kg,100 mg/kg or 50 mg/kg)for four weeks.The body weight,postprandial blood glucose and glycosylated hemoglobin levels were measured during the administration.After the administration,a glucose tolerance test was performed,and the levels of triglycerides,cholesterol and low-density lipoproteins in mice were detected by biochemical test kits.The inhibitory activity of AME onα-glucosidase in vivo and in vitro was determined by enzyme inhibition tests.Results:AME significantly reduced weight gain,postprandial blood glucose,glycosylated hemoglobin and low-density lipoprotein levels in T2DM mice;enhanced glucose tolerance and pancreaticβ-cell function of T2DM mice;inhibitedα-glucosidase activity in mouse intestine in an noncompetitive manner.Conclusion:AME may noncompetitive inhibitα-glucosidase activity and reduce postprandial glucose intake to achieve a therapeutic and regulatory effect on type 2 diabetes.展开更多
目的探究西格列汀治疗2型糖尿病的临床疗效及对患者糖化血红蛋白(HbA_(1)c)、餐后2 h血糖(2 h PBG)水平的影响。方法选取2018年5月至2019年10月于本院就诊的100例2型糖尿病患者作为研究对象,随机分为两组,每组50例。观察组采用西格列汀...目的探究西格列汀治疗2型糖尿病的临床疗效及对患者糖化血红蛋白(HbA_(1)c)、餐后2 h血糖(2 h PBG)水平的影响。方法选取2018年5月至2019年10月于本院就诊的100例2型糖尿病患者作为研究对象,随机分为两组,每组50例。观察组采用西格列汀治疗,对照组采用阿卡波糖治疗,比较两组血糖[空腹血糖(FPG)、2 h PBG、HbA_(1)c]水平、不良反应发生情况、氧化应激指标[丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-PX)、超氧化物歧化酶(SOD)]及临床疗效。结果治疗前,两组FPG、2 h PBG、HbA_(1)c水平比较差异无统计学意义;治疗后,两组FPG、2 h PBG、HbA_(1)c水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为2.00%,低于对照组的20.00%,差异有统计学意义(P<0.05)。治疗前,两组MDA、SOD、GSH-PX水平比较差异无统计学意义;治疗后,两组MDA水平均低于治疗前,SOD、GSH-PX水平均高于治疗前,且观察组MDA水平低于对照组,SOD、GSH-PX水平均高于对照组,差异有统计学意义(P<0.05)。结论西格列汀治疗2型糖尿病效果显著,能降低FPG和2 h PBG水平,值得临床推广应用。展开更多
Ultra rapid lispro(URLi)is a novel formulation of insulin lispro designed to more closely match the physiological insulin response to a meal,with the aim of improving postprandial glucose(PPG)control.We conducted a mu...Ultra rapid lispro(URLi)is a novel formulation of insulin lispro designed to more closely match the physiological insulin response to a meal,with the aim of improving postprandial glucose(PPG)control.We conducted a multinational,multicenter,randomized,double-blind,treat-to-target,26-week,phase 3 trial to evaluate the efficacy and safety of URLi in adults with type 2 diabetes(T2D).After an 8-week lead-in period during which basal insulin glargine or degludec was optimized,adults with T2D were randomized(2:1)to prandial URLi(n=395)or lispro(n=200).The primary endpoint was non-inferiority of URLi versus lispro in glycated hemoglobin A1c(HbA_(1c))change from baseline to week 26.Multiplicity-adjusted analyses were performed to assess the superiority of URLi in 1-and 2-h PPG excursions during a mixed-meal tolerance test(MMTT)and HbA_(1c) change at week 26.URLi showed non-inferiority for Hb Achange at week 26 versus lispro(least-squares mean[LSM]difference,0.07%;95%confidence interval:-0.07,0.21).HbA_(1c) was reduced by 0.56%and 0.63%with URLi and lispro,respectively,with no significant treatment difference(P=0.321).URLi provided superior PPG excursion control versus lispro at1 h(LSM difference:-14.6 mg/d L,P<0.001)and 2 h(LSM difference:-21.8 mg/d L,P<0.001)as well as other time points(30–240 min)during the MMTT.Incremental area under the glucose curve during the MMTT was also significantly lower with URLi versus lispro.The safety profiles were generally similar between treatment groups.In conclusion,URLi was superior to lispro for PPG control,with noninferiority in HbA_(1c) improvement,in adults with T2D.展开更多
文摘Objective:To investigate the relationship between postprandial blood glucose(PBG),fasting insulin(FINS),and glycated hemoglobin(HbA1c)levels and early diabetic nephropathy in patients with type 2 diabetes.Methods:96 cases of type 2 diabetes mellitus treated in our hospital from May 2021 to May 2022 were selected as the research subjects.The patients were divided into two groups according to the urinary albumin excretion rate(UAER),with 53 cases in the type 2 diabetes group(UAER<30μg/min)and 43 cases in the early diabetic nephropathy group(30μg/min≤UAER<300μg/min).PBG,FINS,and HbA1c levels were detected in 87 healthy patients.Results:The levels of PBG,FINS,and HbA1c in the early diabetic nephropathy group were higher than those in the control group(P<0.01)and the type 2 diabetes group(P<0.01).Conclusion:PBG,FINS,and HbA1c are factors affecting the occurrence of diabetic nephropathy in patients with type 2 diabetes;thus,controlling the levels of PBG,FINS,and HbA1c can effectively prevent the occurrence of diabetic nephropathy in type 2 diabetes mellitus.
文摘目的分析糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)单一及联合检验诊断糖尿病的价值。方法以72例疑似有糖尿病的患者作为临床研究对象,均接受HbA1c、FPG、2 h PG检验,以糖耐量测定为诊断“金标准”。比较HbA1c、FPG、2 h PG单一及联合检验的灵敏度、特异度、准确度。结果72例受检者中有58例患者确诊为糖尿病。联合检验的诊断灵敏度、特异度、准确度分别为94.83%、92.86%、94.44%;HbA1c检验的诊断灵敏度、特异度、准确度分别为75.86%、28.57%、66.67%;FPG检验的诊断灵敏度、特异度、准确度分别为81.03%、35.71%、72.22%;2 h PG检验的诊断灵敏度、特异度、准确度分别为77.59%、42.86%、70.83%。联合检验诊断的灵敏度、特异度及准确度均高于其他HbA1c、FPG、2 h PG单一诊断的灵敏度、特异度及准确度,具有统计学意义(P<0.05)。结论HbA1c、FPG、2 h PG联合检验相较单一检验诊断糖尿病具有较高的临床价值,能够为临床治疗提供有价值的参考依据。
基金supported by 2020 College Students Innovation and Entrepreneurship Training Program(X202011810069)the National Natural Science Foundation of China(81460591)。
文摘Objective:To explore the anti-diabetic effects and its underlying mechanism of Annona muricata Linn fruit ethanol extract(AME).Methods:Streptozotocin-induced type 2 diabetic(T2DM)mouse model was constructed.Those diabetic mice were randomly grouped and given 50 mg/kg acarbose or AME(200 mg/kg,100 mg/kg or 50 mg/kg)for four weeks.The body weight,postprandial blood glucose and glycosylated hemoglobin levels were measured during the administration.After the administration,a glucose tolerance test was performed,and the levels of triglycerides,cholesterol and low-density lipoproteins in mice were detected by biochemical test kits.The inhibitory activity of AME onα-glucosidase in vivo and in vitro was determined by enzyme inhibition tests.Results:AME significantly reduced weight gain,postprandial blood glucose,glycosylated hemoglobin and low-density lipoprotein levels in T2DM mice;enhanced glucose tolerance and pancreaticβ-cell function of T2DM mice;inhibitedα-glucosidase activity in mouse intestine in an noncompetitive manner.Conclusion:AME may noncompetitive inhibitα-glucosidase activity and reduce postprandial glucose intake to achieve a therapeutic and regulatory effect on type 2 diabetes.
文摘目的:探索“建康1号”大米对2型糖尿病(type 2 diabetes mellitus,T2DM)患者餐后血糖的影响。方法:选取T2DM患者24例(男性14例,女性10例),采用自身对照,同一患者前3 d食用主食为普通白米的标准配餐,洗脱期后3 d食用主食为“建康1号”大米的标准配餐。观察患者在对应时间,餐后最高血糖较空腹血糖的增幅、72 h血糖连续监测下血糖目标范围内时间(time in range,TIR)、血糖曲线下面积(area under the curve,AUC)的变化。结果:食用主食为“建康1号”大米的患者餐后最高血糖、TIR、AUC均显著优于食用普通白米者(P<0.05)。结论:相较于普通白米,食用“建康1号”大米可改善T2DM患者的餐后血糖。
文摘目的探究西格列汀治疗2型糖尿病的临床疗效及对患者糖化血红蛋白(HbA_(1)c)、餐后2 h血糖(2 h PBG)水平的影响。方法选取2018年5月至2019年10月于本院就诊的100例2型糖尿病患者作为研究对象,随机分为两组,每组50例。观察组采用西格列汀治疗,对照组采用阿卡波糖治疗,比较两组血糖[空腹血糖(FPG)、2 h PBG、HbA_(1)c]水平、不良反应发生情况、氧化应激指标[丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-PX)、超氧化物歧化酶(SOD)]及临床疗效。结果治疗前,两组FPG、2 h PBG、HbA_(1)c水平比较差异无统计学意义;治疗后,两组FPG、2 h PBG、HbA_(1)c水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为2.00%,低于对照组的20.00%,差异有统计学意义(P<0.05)。治疗前,两组MDA、SOD、GSH-PX水平比较差异无统计学意义;治疗后,两组MDA水平均低于治疗前,SOD、GSH-PX水平均高于治疗前,且观察组MDA水平低于对照组,SOD、GSH-PX水平均高于对照组,差异有统计学意义(P<0.05)。结论西格列汀治疗2型糖尿病效果显著,能降低FPG和2 h PBG水平,值得临床推广应用。
文摘Ultra rapid lispro(URLi)is a novel formulation of insulin lispro designed to more closely match the physiological insulin response to a meal,with the aim of improving postprandial glucose(PPG)control.We conducted a multinational,multicenter,randomized,double-blind,treat-to-target,26-week,phase 3 trial to evaluate the efficacy and safety of URLi in adults with type 2 diabetes(T2D).After an 8-week lead-in period during which basal insulin glargine or degludec was optimized,adults with T2D were randomized(2:1)to prandial URLi(n=395)or lispro(n=200).The primary endpoint was non-inferiority of URLi versus lispro in glycated hemoglobin A1c(HbA_(1c))change from baseline to week 26.Multiplicity-adjusted analyses were performed to assess the superiority of URLi in 1-and 2-h PPG excursions during a mixed-meal tolerance test(MMTT)and HbA_(1c) change at week 26.URLi showed non-inferiority for Hb Achange at week 26 versus lispro(least-squares mean[LSM]difference,0.07%;95%confidence interval:-0.07,0.21).HbA_(1c) was reduced by 0.56%and 0.63%with URLi and lispro,respectively,with no significant treatment difference(P=0.321).URLi provided superior PPG excursion control versus lispro at1 h(LSM difference:-14.6 mg/d L,P<0.001)and 2 h(LSM difference:-21.8 mg/d L,P<0.001)as well as other time points(30–240 min)during the MMTT.Incremental area under the glucose curve during the MMTT was also significantly lower with URLi versus lispro.The safety profiles were generally similar between treatment groups.In conclusion,URLi was superior to lispro for PPG control,with noninferiority in HbA_(1c) improvement,in adults with T2D.
